22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The DE OFCCP Week in Review (WIR) is a simple, fast and direct summary of relevant happenings in the...
Read More >
Welcome to the second 2019 issue of Product Lines – our quarterly e-newsletter that focuses on toxi...
Read More >
On April 16, 2020, sixteen California legislators urged Bay Area counties to relax the restrictions ...
Read More >
Disclosure-based strike suits have died an inglorious and richly-deserved death in Delaware. Lest de...
Read More >
Title VII of the Civil Rights Act requires employers in the healthcare industry to provide a reasona...
Read More >
In 2012, Congress passed and President Obama signed the “Moving Ahead for Progress in the 21st Cent...
Read More >